Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRadiopharm Theranostics Ltd

Radiopharm Theranostics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.004 AUD 0.00(0%)
Last update at 2026-11-09T05:10:00Z
VOLUME
26084275
Market Cap
18.84M

Momentum Score

…

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Radiopharm Theranostics Ltd develops and seeks to commercialize radiopharmaceutical therapies and diagnostic agents for oncology while supporting radiochemistry and isotope supply for clinical use. Long-term growth drivers include rising demand for targeted cancer treatments and molecular theranostics, potential commercialisation of its development programs, and broader adoption of precision oncology, which may benefit investors seeking specialty oncology exposure.
Key risks include clinical and regulatory failure, manufacturing and supply-chain complexity for radioisotopes, high capital requirements and a limited commercial track record.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
12.87M
Revenue Per Share
0.00
Gross Profit TTM
-34.34M
Debt / Equity
-
ROE
-174.71%
Net Debt
-4.14M
ROCE
-165.70%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -56.90M -38.24M -47.85M -34.57M -30.29M
Net income -55.15M -36.70M -47.95M -34.61M -30.34M
Selling general administrative - 14.64M 13.04M 15.26M 12.44M
Selling and marketing expenses - 1.90M 2.18M - -
Gross profit -2.15M 9.81M -21.31M 0.29M 0.01M
Reconciled depreciation - 0.01M 3.13M 3.30M 2.98M
Ebit -68.33M -34.24M -48.50M -28.59M -23.93M
Ebitda -68.32M -31.65M -45.38M -31.19M -20.94M
Depreciation and amortization 0.01M 2.60M 3.13M - 2.98M
Operating income -68.33M -38.17M -47.21M -34.49M -23.93M
Other operating expenses 71.10M 51.57M 36.92M - 20.95M
Interest expense 0.11M 0.07M 0.64M 0.26M 9.35M
Tax provision - 0.10M 0.10M 0.04M 0.04M
Interest income - 0.89M 0.05M 0.09M 9.35M
Net interest income - 0.33M -0.59M 0.06M -9.35M
Income tax expense -0.05M 0.10M 0.10M 0.04M 0.04M
Total revenue 2.77M 13.40M 0.30M 0.29M 0.01M
Total operating expenses 66.18M 47.98M 27.56M - 20.95M
Cost of revenue 4.92M 3.59M 21.61M - -
Total other income expense net 11.43M -0.07M -0.64M -0.12M -1.03M
Net income from continuing ops - -38.34M -47.95M -34.61M -30.34M
Net income applicable to common shares - -38.34M -47.95M -34.61M -30.42M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 60.13M 86.48M 72.04M 74.95M 83.38M
Intangible assets - 46.57M - 58.54M 56.08M
Other current assets 0.34M 0.34M 3.29M 0.13M 0.23M
Total liab 37.81M 43.61M 44.68M 30.57M 20.42M
Total stockholder equity 24.69M 44.79M 28.12M 44.38M 62.96M
Other current liab 12.62M 3.42M 11.14M 8.16M 6.69M
Common stock 209.93M - 100.68M 97.23M 86.76M
Capital stock - 176.56M - 97.23M 86.76M
Retained earnings -199.66M -145.73M -111.34M -65.35M -30.82M
Other liab - - - 16.14M 12.54M
Other assets - - - 0.04M 0.04M
Cash 4.14M 29.12M 18.58M 11.70M 26.98M
Total current liabilities 18.90M 14.93M 17.58M 13.23M 7.88M
Current deferred revenue 0.81M - - - -
Net debt -4.14M - -18.58M - -26.98M
Short term debt - - - 0.00M 0.00M
Other stockholder equity 14.41M - 37.93M 12.51M 7.11M
Property plant equipment - - - 0.07M 0.00M
Total current assets 21.93M 39.85M 22.85M 16.30M 27.26M
Long term investments - 0.00M - - -
Net tangible assets - - - -14.16M 6.89M
Net receivables 17.45M - 0.99M 4.47M 0.06M
Accounts payable 5.47M 6.35M 6.43M 2.96M 1.19M
Accumulated other comprehensive income - - 0.85M - 7.03M
Non currrent assets other - - 49.09M 0.04M 0.04M
Non current assets total 38.21M 46.63M 49.19M 58.65M 56.12M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 1.77M -0.32M -1.53M -0.04M
Change to liabilities - - - 2.35M 2.53M
Total cashflows from investing activities -5.42M 1.77M 0.00M -1.53M -28.38M
Net borrowings - -1.90M 2.20M - -0.06M
Total cash from financing activities 33.37M 45.43M 29.88M 9.22M 65.11M
Change to operating activities - - - 0.10M -0.23M
Net income -55.15M -36.70M -47.95M -34.61M -30.42M
Change in cash -24.98M 10.54M 6.88M -15.28M 26.95M
Begin period cash flow 29.12M 18.58M 11.70M 26.98M 0.03M
End period cash flow 4.14M 29.12M 18.58M 11.70M 26.98M
Total cash from operating activities -52.78M -36.65M -22.98M -23.20M -9.91M
Issuance of capital stock - 53.98M 29.65M 10.07M 70.00M
Depreciation 0.01M 2.60M 3.13M 3.30M 2.98M
Other cashflows from investing activities - 1.77M 0.00M 0.00M 0.01M
Change to account receivables - -9.41M 3.48M 1.51M -0.05M
Sale purchase of stock - 53.98M -1.53M 10.07M -4.83M
Other cashflows from financing activities - -1.91M -0.44M -0.85M 0.01M
Change to netincome - - - 4.16M 15.28M
Capital expenditures 52.78M 0.00M 0.00M 0.05M 28.34M
Change in working capital - -5.95M 7.05M 1.70M 0.01M
Stock based compensation - 1.90M 2.64M - -
Other non cash items 2.36M 1.52M 12.15M - -
Free cash flow - -36.65M -22.98M -24.73M -28.34M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RAD
Radiopharm Theranostics Ltd		 -
-%		 0.00 - - 1.46 0.76 5.31 0.42
CSL
CSL Ltd		 -1.27
0.63%		 200.77 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 0.26
1.90%		 13.93 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 0.60
2.58%		 23.84 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 0.01
0.49%		 2.04 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Radiopharm Theranostics Ltd

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.

62 Lygon Street, Carlton, VIC, Australia, 3053

61 3 9824 5254

https://www.radiopharmtheranostics.com

14

Name Title Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Exec. Chairman 1956
Mr. Riccardo Canevari MD, CEO & Director NA
Mr. Phillip Hains CFO & Company Sec. NA
Prof. David Mozley Chief Medical Officer & Scientific Advisory Board Chair NA
Mr. Vittorio Puppo M.D. Chief Operating Officer NA
Dr. Thomas H. Tulip Ph.D. Chief Technical Officer 1953
Dr. Scot L. Harper Ph.D. Sr. VP of Clinical Operations 1957
Mr. Bill Regan Sr. VP of Regulatory Strategy NA
Mr. Nathan Jong C.A. Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Executive Chairman 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…